Developing novel Lin28 inhibitors by computer aided drug design.

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Lin28 is a critical regulator of cancer stem cell networks, driving therapy-resistant tumor progression.
• Existing Lin28 inhibitors lack clinical approval, necessitating the search for novel therapeutic agents.

Purpose of the Study:

• To discover and characterize novel compounds that inhibit Lin28 activity for potential cancer therapy.
• To validate a computer-aided drug design (CADD) approach for identifying Lin28 inhibitors.

Main Methods:

• Computer-aided drug design (CADD) was employed to identify potential Lin28 inhibitors.
• Quantitative biochemical and biological assays were used to assess compound efficacy.
• Nuclear magnetic resonance (NMR) spectroscopy confirmed the molecular interaction of the drug candidate with Lin28.

Main Results:

• Ln268 was identified as a potent inhibitor that blocks Lin28 binding to RNA substrates and inhibits its activity.
• Ln268 suppressed cancer cell proliferation and spheroid growth, with effects dependent on Lin28 expression.
• NMR confirmed Ln268 perturbs the Lin28 zinc knuckle domain, validating the CADD approach.
• Ln268 demonstrated synergy with conventional chemotherapy drugs.

Conclusions:

• Ln268 is a promising drug candidate for targeting Lin28 in cancer therapy.
• The study validates the use of CADD in discovering targeted cancer therapeutics.
• Ln268 exhibits specific inhibitory effects and potential for combination therapy.